Adam Zaeske serves as Executive Vice President and Chief Commercial Officer at Harmony Biosciences Holdings Inc., a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare neurological diseases. In this pivotal role, he leads the company's commercial organization, overseeing sales, marketing, market access, and trade strategies to drive the growth and accessibility of key products like WAKIX (pitolisant), the first-and-only treatment approved by the FDA for both excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. Under his leadership, Harmony has solidified its position as a leader in the narcolepsy market, expanding patient reach and achieving significant revenue milestones. With over 25 years of experience in the pharmaceutical industry, Zaeske brings a proven track record of building high-performing commercial teams and launching blockbuster products. Prior to joining Harmony in 2020, he held senior leadership positions at Alexion Pharmaceuticals, where he served as Senior Vice President of U.S. Commercial Operations, spearheading the launch of rare disease therapies and driving multi-billion-dollar revenue growth. His earlier career included key roles at Shire Pharmaceuticals, focusing on neurology and rare diseases, as well as positions at Pfizer and GlaxoSmithKline, where he honed his expertise in strategic commercialization and market expansion. Zaeske's achievements include successfully scaling commercial infrastructures for orphan drug launches, fostering cross-functional collaborations, and navigating complex payer environments to enhance patient outcomes. At Harmony, he has been instrumental in achieving over $500 million in annual net product revenues for WAKIX within its first few years post-launch, while expanding the commercial footprint to support the company's pipeline advancements in other rare neurological disorders. His strategic vision continues to propel Harmony's mission of transforming lives for underserved patient communities.